Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,166 across all filing types
Latest filing 2025-07-01 Capital/Financing Update
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin Carves Out LupinLife Consumer Healthcare.
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the strategic carve-out of Lupin's consumer healthcare business into a wholly owned subsidiary. It is addressed to stock exchanges and references compliance with SEBI regulations. The content focuses on corporate restructuring and business strategy rather than financial results or detailed financial data. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The document is informational and intended for public dissemination of a corporate action. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to a significant corporate restructuring involving business carve-out and subsidiary formation.
2025-07-01 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the strategic carve-out of Lupin's consumer healthcare business into a wholly owned subsidiary. It is addressed to stock exchanges and references compliance with SEBI regulations. The content focuses on the business restructuring and leadership appointment, without any financial statements or detailed financial performance data. The document length is about 5,079 characters, which is relatively short and typical for a press release. There is no indication that this is a full financial report, audit report, or regulatory filing. It is an announcement of a corporate action related to business restructuring, which fits best under Capital/Financing Update (CAP) as it involves a significant change in company structure and capital allocation strategy. Therefore, the classification is CAP with high confidence.
2025-07-01 English
Execution of Business Transfer Agreement for transfer of its API R&D Division situated at Pune, to Lupin Manufacturing Solutions Limited, a wholly owned subsidiary of the Company, on a ....
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI Listing Regulations, informing about the execution of a Business Transfer Agreement (BTA) for transfer of a division within the company. It is a regulatory announcement about a business transaction (transfer of API R&D Division) but does not contain financial statements, detailed financial analysis, or full report content. The document length is short (1923 characters) and serves as an official notification to the stock exchanges. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like M&A filings or capital updates, since it is about a business transfer within the company on a slump sale basis but not a merger or acquisition per se. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-06-30 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is a notification to stock exchanges under Regulation 30 of SEBI Listing Regulations about the execution of a Business Transfer Agreement (BTA) for transfer of a division within the company. It is an announcement of a corporate transaction (business transfer on a slump sale basis) but does not contain financial statements, detailed financial analysis, or full report content. The document is short (1923 characters) and serves as an update on a capital restructuring event within the company. This fits best under Capital/Financing Update (CAP) as it relates to changes in the company's business structure and capital allocation rather than a full report or regulatory filing.
2025-06-30 English
Execution of Business Transfer Agreement for transfer of its Over-the Counter Consumer Healthcare Business to LUPINLIFE Consumer Healthcare Limited, a wholly owned subsidiary of the Company, ....
Capital/Financing Update Classification · 95% confidence The document is a notification to stock exchanges under Regulation 30 of the SEBI Listing Regulations, indicating the execution and completion of a Business Transfer Agreement (BTA) for the transfer of a business segment to a wholly owned subsidiary. It is an intimation about a corporate transaction (business transfer) rather than a full report or detailed financial disclosure. The document is short (1994 characters) and serves as an announcement of a corporate action related to business restructuring or transfer. This fits best under Capital/Financing Update (CAP) as it relates to a significant change in the company's business structure and capital arrangement through a slump sale to a subsidiary. It is not an annual or interim report, audit report, or earnings release, nor is it a regulatory filing or management change announcement. Therefore, the classification is CAP with high confidence.
2025-06-30 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is a notification to stock exchanges under Regulation 30 of the SEBI Listing Regulations, indicating the execution and completion of a Business Transfer Agreement (BTA) for the transfer of a business segment to a wholly owned subsidiary. It is an announcement of a corporate transaction (business transfer) rather than a detailed report or financial statement. The document length is short (1994 characters) and it serves as an intimation or update about a capital structure or business change event. This fits best under Capital/Financing Update (CAP) as it relates to a significant business transfer and restructuring event affecting the company's capital or business segments.
2025-06-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.